Hamburg Edoxaban for Anticoagulation in COVID-19 Study
Launched by UNIVERSITÄTSKLINIKUM HAMBURG-EPPENDORF · Sep 6, 2020
Trial Information
Current as of May 18, 2025
Completed
Keywords
ClinConnect Summary
Coagulopathy in the context of COVID-19 is a major threat to affected patients due to deep vein thromboses and pulmonary embolisms. Actual data show an unexpectedly high incidence of partially fatal complications without any prior clinical evidence in some cases. Therefore, this prospective, randomized, assessor-blinded, multicenter, placebo-controlled, interventional trial will investigate whether therapeutic anticoagulation on top of SOC compared to prophylactic anticoagulation as part of SOC- can improve objective patient-relative endpoints, relevant for prognosis in patients with COVID-...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Diagnosis of COVID-19 and hospitalization on ICU, or
- • Diagnosis of COVID-19 and hospitalization on normal ward, or
- • Diagnosis of COVID-19 (within 10 days) and troponin ≥ ULN and/or D-dimer ≥0.5 mg/L
- Exclusion Criteria:
- • Age below 18
- • Life expectancy less than 3 months before COVID-19
- • Resuscitation \> 30 minutes
- • Hypersensitivity to the active substance, to Edoxaban or any of its excipients
- • Significantly increased bleeding risk
- • Other indication for anticoagulation beyond COVID-19
- • GFR \< 15 ml/min
- • Planned transfer of the patient to another clinic within the next 42 days
About Universitätsklinikum Hamburg Eppendorf
Universitätsklinikum Hamburg-Eppendorf (UKE) is a leading academic medical center in Germany, renowned for its commitment to advancing healthcare through innovative research and clinical excellence. As a prominent sponsor of clinical trials, UKE integrates state-of-the-art facilities with a multidisciplinary approach, fostering collaboration among top-tier researchers, clinicians, and healthcare professionals. The institution is dedicated to improving patient outcomes by conducting rigorous scientific investigations that address critical health challenges, ultimately contributing to the development of novel therapies and enhancing medical knowledge.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Düsseldorf, , Germany
Freiburg, , Germany
Hamburg, , Germany
Hanover, , Germany
Hamburg, , Germany
Hamburg, , Germany
Augsburg, , Germany
Aachen, , Germany
Hamburg, , Germany
München, , Germany
Patients applied
Trial Officials
Stefan Kluge, MD
Principal Investigator
Universitätsklinikum Hamburg-Eppendorf
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials